H.I.V

An influential expert panel has given its highest recommendation to an expanded menu of H.I.V. prevention strategies for adults and adolescents, a move that will require private insurers to cover the drugs without a co-pay or deductible…

In 2004, Gilead Sciences decided to stop pursuing a new H.I.V. drug. The public explanation was that it wasn’t sufficiently different from an existing treatment to warrant further development.In private, though, something else was at play.…

While the world’s attention was riveted on the Covid pandemic and the war in Ukraine, the fight against an older foe lost crucial ground: More than 1.5 million people became infected with H.I.V. last year, roughly three times the global…